You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on lung cancer.
Increasing understanding of complex tumor biology is reshaping clinical trials in the age of precision medicine, though some view these changes with concern.
The finding suggests that African-American patients may be more likely to respond to treatment with poly ADP ribose polymerase (PARP) inhibitors.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek.
The approval is based on a Phase III trial showing that Tecentriq significantly improved survival in patients with metastatic non-small cell lung cancer.
At least one drugmaker is planning to submit for FDA approval of its KRAS inhibitor based on data from Phase I/II, single-arm trial in heavily pretreated lung cancer patients.
The company will use its InVisionFirst-Lung test to study resistance mutations in patients treated with Pfizer's ALK inhibitor lorlatinib.
The ROS1ders advocacy group is 500 patients strong and they are helping researchers establish cell lines to improve understanding of rare ROS1-positve cancers.
Researchers have shown that the use of antibiotics in the weeks leading up to immunotherapy may lessen a patients' response to the treatment.
The company has collected initial evidence for an algorithmic method to predict immunotherapy response, and is studying its technology in treatment monitoring.